Cardiovascular

Novartis announces good heart drug results

Novartis announces good heart drug results

By

The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.

Analyst gives PCSK9 preview

Analyst gives PCSK9 preview

By

Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.

Hawaii sues BMS, Sanofi over Plavix

The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.

Old guidelines boosted Zetia prescriptions

Old guidelines boosted Zetia prescriptions

By

Researchers find that Canada has been a significant contributor to Zetia sales.

Study says fat may not be the villain

Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.

Eliquis enters the DVT business

Eliquis enters the DVT business

By

The FDA approved the blood drug to prevent deep vein thrombosis and pulmonary embolism among hip- and knee-replacement patients. The approval means BMS and Pfizer may encroach upon the territory of J&J's Xarelto.

Amgen's PSCK9 shows rare disease potential

Amgen's PSCK9 shows rare disease potential

By

The Thousand Oaks, Calif. company says its cholesterol-lowering antibody hit its clinical trial endpoint among rare disease patients.

Takeda admits running bad ads

The company said it used "inappropriate expressions" in promotions of a blood pressure medication.

Roche halts lung drug combo test

Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.

Xarelto indication stays as-is

The FDA rejected J&J's expanded indication request a third time.

Study finds heart health knowledge lacking

The Cleveland Clinic finds that 75% of Americans don't worry about dying of heart disease, even though it's the country's leading killer.

Complaint heaps more concerns on Brilinta study

A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.

Ph.III results a boost for Amgen in PCSK9 race

Ph.III results a boost for Amgen in PCSK9 race

By

Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.

Panel endorses Merck's anti-clotting drug

The FDA panel voted 10-1 for the drug. The assessment included patient weight and health recommendations.

Discontinued OTC asthma med may make comeback

An FDA committee is poised to review a new Primatene Mist in February.

UPDATE: Pradaxa comes under scrutiny again

UPDATE: Pradaxa comes under scrutiny again

By

The warfarin replacement will be evaluated in a post-trial safety study, regulators said last Friday.

Sanofi, Regeneron PCSK9 trial uses new recruitment tool

The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.

Judge slaps Boehringer with $931K fine

The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.

Poll: Statin use will grow modestly

Poll: Statin use will grow modestly

By

A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.

Delayed Anthera data release shows increased heart risk

The drugmaker revealed the data a year after stopping a Phase III trial.

Daiichi Sankyo blood thinner fails to wow

Daiichi Sankyo blood thinner fails to wow

By

Phase III clinical trial results underwhelm investors who feel on-market drugs offer better patient value.

BI tests new Pradaxa uses, antidote may be in the works

The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.

Cholesterol guidelines setback

The calculator meant to help doctors use the new cholesterol guidelines appears to be flawed.

Putting the big picture ahead of LDL levels

Putting the big picture ahead of LDL levels

By

Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.

Ariad hunkers down

Ariad hunkers down

By

The drugmaker's latest financial plans could power it through mid-2015.

GSK misses on late-stage CV drug

GSK misses on late-stage CV drug

By

An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.

Amarin's hopes for Vacepa dim

The FDA told the drugmaker in a letter before the December PDUFA date that evidence does not support an expanded indication.

Panel votes against Amarin fish oil

An advisory committee voted 9 to 2 against expanding the drug's indication.

Lilly employees charged with IP theft

Three former workers are accused of giving proprietary data to a drug company abroad.

Bayer: 5 new Phase III drugs expected in 2015

The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.

Email Newsletters